• Stemedica Opens Enrollment in Phase II Clinical Trial for COVID-19 prnewswire
    August 06, 2021
    Stemedica announces enrollment of patients for its study entitled "A Phase II, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Moderate.
PharmaSources Customer Service